ESG

ESG Mission

Our mission is to "Serve Life, Guard Health". We continue to innovate our management and technology to provide our customers with high-quality products while working with stakeholders to strengthen our practices around environmental stewardship, social responsibility, and corporate governance in order to build a sustainable future together.

ESG Honors

ESG
ESG HONOR-1
ESG HONOR-2
ESG HONOR-3
ESG HONOR-4
ESG HONOR-5
ESG HONOR-6
ESG HONOR-7
ESG HONOR-8

ESG Management Structure

Jiuzhou Pharma established a Strategic Decision-Making Committee that oversees sustainability and ESG issues to ensure the company's continued, compliant, and robust development, further improve the governance structure, and advance environmental, social, and governance initiatives.

ESG Management Structure

The Strategic Decision-Making Committee, chaired by the Board Chair, is a special committee under the Board of Directors. Its primary responsibilities in sustainability and ESG encompass analysis of global economic and industry trends, ESG strategy formulation, ESG risk identification, ESG performance evaluation, and ESG oversight.


The ESG Executive Committee, chaired by the Board Secretary, consists of department managers at the headquarters. The Executive Committee regularly convenes meetings to discuss ESG planning and progress, government policies, and industry trends in light of progress on ESG issues.


The ESG Working Group is responsible for daily sustainability and ESG matters. The Working Group collaborates with all relevant functional and business units to implement sustainability and ESG strategies and measures.

The Strategic Decision-Making Committee


The Strategic Decision-Making Committee, chaired by the Board Chair, is a special committee under the Board of Directors. Its primary responsibilities in sustainability and ESG encompass analysis of global economic and industry trends, ESG strategy formulation, ESG risk identification, ESG performance evaluation, and ESG oversight.

The ESG Executive Committee


The ESG Executive Committee, chaired by the Board Secretary, consists of department managers at the headquarters. The Executive Committee regularly convenes meetings to discuss ESG planning and progress, government policies, and industry trends in light of progress on ESG issues.

The ESG Working Group


The ESG Working Group is responsible for daily sustainability and ESG matters. The Working Group collaborates with all relevant functional and business units to implement sustainability and ESG strategies and measures.

ESG Policy

Environment

Topics of Concern

Climate change mitigation and adaptation

Environmental management

Emissions management

Water management

Resource conservation and utilization

Green chemistry

Our Objective

Climate change mitigation and adaptation:

By 2030, greenhouse gas emissions per unit of revenue (Scope 1 and 2) will be reduced by 25% compared to 2023;

By 2030, achieve carbon peak in its own operations (Scope 1 and 2);

By 2030, more than 50% of renewable energy will be used.

Environmental management:

By 2030, more than 80% of our operations will be ISO 14001 certified (or other equivalent or similar standards).

Water management:

By 2030, water consumption per unit of revenue will be reduced by 20% compared to 2023.

Emissions management:

By 2030, the company's waste gas, wastewater, and solid waste will be treated in compliance, and the noise at the plant boundary will be discharged up to standard;

By 2030, reduce waste emissions per unit of revenue by 30% compared to 2021 (including hazardous and non-hazardous waste).

Our Policies

Social

Topics of Concern

Sustainable supply chain management

Service Quality Improvement

Innovation and R&D

Employee Rights and Benefits

Occupational Health and Safety

Data Security and Privacy Protection

Employee Training and Development

Intellectual Property Protection

Responsible Marketing

Community Health and Social Welfare

Contribute to The Development of The Industry

Sustainable supply chain management

Service quality improvement

Innovation and R&D

Employee rights and benefits

Occupational health and safety

Data security and privacy protection

Employee training and development

Intellectual property protection

Responsible marketing

Community health and public welfare

Contribute to the development of the industry

Our Objective

Sustainable supply chain management:

By 2030, 80% of suppliers will have signed contractual clauses that include social and environmental commitments.

By 2030, 100% of strategic and key suppliers will sign the Supplier Code of Conduct, have received social responsibility questionnaires, on-site assessments, and ESG training or other ESG capacity building counseling;

By 2030, 100% of our procurement staff will be trained in sustainable awareness for procurement.

Service quality improvement:

By 2030, the customer complaint rate will be maintained below 5% and the customer complaint response rate will be maintained at 100%;

By 2030, there will be zero product recalls.

Data security and privacy protection:

By 2030, ISO27001 information security management system certification will cover all data centers of Jiuzhou Pharma.

By 2030, at least one information security awareness training is conducted per year, covering more than 95% of employees.

Intellectual property protection:

By 2030, there will be no violations of laws and regulations related to intellectual property rights every year.

Innovation and R&D:

Actively practice the "12 Principles of Green Chemistry", reduce pollutant and waste emissions per unit of revenue by 30% (including hazardous and non-hazardous waste) by 2030 compared with 2021, and improve the application of green pharmaceutical technologies such as biocatalysis and continuous flow in commercial products.

Employee training and development:

By 2030, the annual employee training coverage rate will be maintained at greater than 95%;

By 2030, 100% coverage of performance appraisal and career development appraisal;

By 2030, the average number of hours of training per employee will increase by 30% compared to 2021.

Employee rights and benefits:

By 2030, conduct anti-discrimination and anti-harassment awareness training at least once a year, covering 95% of all employees;

By 2030, the proportion of new employees in each year will not be less than 30% female;

Establish a diverse management team and ensure that the management team is diverse in terms of educational background, professional experience, gender, age, and ethnicity (nationality) to enhance decision-making and innovation.

Occupational health and safety:

By 2030, more than 80% of operations will be ISO 45001 certified (or other equivalent or similar standards).

By 2030, the number of work-related deaths will be maintained at 0 per year.

By 2030, the total lost worktime rate per million per year due to accidents will remain below 0.85.

Our Policies

Governance

Topics of Concern

Business Ethics

Corporate Governance and Information Transparency

Compliance

Risk Management

ESG management

Business ethics

Corporate governance and information transparency

Compliance

Risk management

ESG management

Our Objective

Corporate governance and information transparency:

Promote diversity on the board of directors, and consider multi-dimensions comprehensively, such as educational background, industry experience, age, and gender in the election of directors.

Business ethics:

Conduct at least one business ethics and anti-corruption awareness training per year, more than 95% training coverage by 2030;

At least every three years, we will conduct anti-corruption audits covering all business processes, and by 2030, ensure that more than 80% of the company's operations have received business ethics internal audits.

Our Policies

ESG Report

Business Collaboration

Innovative Drug CDMO Services

Established Business Services(API)

Human Resources

Join Us

Jiuzhou

LinkedIn

License

Powered by 300.cn

Business Collaboration

Innovative Drug CDMO Services

Established Business Services(API)

Human Resources

Join Us




[Multiple]Interested business area:
Small Molecule CDMO Services
CDMO-Preparations
CDMO-Polypeptide
Generic drug Service
Registration & Regulatory Service
Animal Health Services